The Decent Value screen applies a value investing discipline that goes beyond simply buying the lowest price-to-earnings ratio. The methodology starts with valuation but then requires that a company also demonstrates acceptable profitability, financial health, and growth. In other words, it is designed to find stocks that look cheap for a good reason rather than because the business is deteriorating. One name that currently stands out is SMITH & NEPHEW PLC -SPON ADR (NYSE:SNN), a medical device company active in orthopaedics, sports medicine, ENT, and advanced wound management.
What the Decent Value screen looks for
The screen begins with a valuation filter, looking for companies that score well on metrics such as price/earnings, forward earnings, EV/EBITDA, and price/free cash flow. But it then adds quality checks: the company must still show decent profitability, a reasonably healthy balance sheet, and at least moderate growth.
That combination matters because a low valuation is only meaningful if the underlying business can maintain its earnings power. Without those checks, value investors risk falling into a value trap, where a cheap stock stays cheap because fundamentals deteriorate.
Valuation: a cheap entry point relative to quality
SNN receives a valuation score of 7/10. On a trailing price/earnings basis, the stock trades at 19.29, below the industry average and well below the S&P 500's 26.27. The forward P/E is more striking at 10.85, which is cheaper than 94.12% of industry peers and far below the S&P 500 forward multiple of 21.76.
The valuation picture is also supported by other multiples:
- EV/EBITDA: SNN is cheaper than 95.72% of industry peers.
- Price/free cash flow: SNN is cheaper than 95.19% of industry peers.
- Price/forward earnings: the 10.85 ratio points to a very reasonable expected earnings base.
The PEG ratio is flagged as less attractive, which is a reminder that the stock is not necessarily inexpensive on a growth-adjusted basis. Still, the company's strong profitability rating may justify a higher multiple than the market currently assigns.
Investors who want to dig deeper into these valuation inputs and the full peer comparison can review the fundamental analysis report.
Profitability and health: quality behind the price
SNN's profitability score is 8/10, its strongest fundamental area. The company has been profitable in each of the past five years and has generated positive operating cash flow over the same period. Return on assets is 5.77%, return on equity is 12.26%, and return on invested capital is 9.44%, each among the better results in its industry. An operating margin of 17.41% is particularly strong, outperforming more than 90% of industry peers.
Health is more mixed. SNN scores 6/10. An Altman-Z score of 3.06 suggests no immediate bankruptcy risk, and a current ratio of 2.14 points to adequate short-term liquidity. However, the quick ratio of 1.11 and a debt/equity ratio of 0.72 are less impressive relative to peers, while a debt/free cash flow ratio of 4.43 means it would take more than four years of free cash flow to repay current debt. These are not red flags, but they explain why the health rating is not higher.
For a value-oriented strategy, this trade-off is acceptable. A healthy balance sheet supports the idea that the company can keep funding its operations and dividend while the market eventually recognizes the underlying earnings power.
Growth: moderate but supportive
The growth score is 5/10, reflecting moderate but positive expansion. Last year, earnings per share grew 31.68%, while historical EPS growth comes in at 6.98% per year. Revenue grew 5.99% last year and 6.21% on average over prior years.
Looking forward, the report expects EPS growth of 8.89% per year and revenue growth of 5.98% per year. That implies a slight acceleration in earnings, which is relevant because it helps support the forward P/E of 10.85. Growth matters for the Decent Value methodology because it can close the gap between market value and intrinsic value over time, without relying on multiple expansion alone.
Key fundamental highlights
The report's overall fundamental rating for SNN is 7/10. The main data points supporting that score include:
- Valuation score: 7/10; forward P/E of 10.85 is cheaper than 94.12% of industry peers.
- Profitability score: 8/10; ROIC of 9.44% outperforms 88.77% of the industry.
- Health score: 6/10; Altman-Z of 3.06 points to limited bankruptcy risk, although quick ratio and debt/equity trail some peers.
- Growth score: 5/10; EPS growth is expected to accelerate from 6.98% historical to 8.89% forward.
- Dividend yield: 2.95%, above the S&P 500 average and higher than 96.79% of industry peers.
Risks and limitations
Value investors should not ignore the less favorable parts of the report. The PEG ratio is elevated, which means the cheap trailing multiple may look less compelling once growth is factored in. Dividend sustainability is acceptable, but the payout ratio of 52.44% leaves limited room for aggressive increases.
In addition, some health metrics are not at the top of the industry, and the company remains exposed to competitive and regulatory pressures in medical devices. As with any value screen, the goal is to reduce risk, not eliminate it. Position sizing and a margin of safety remain important tools for investors who decide to act on this type of setup.
Other screens that reinforce the SNN value case
The Decent Value signal on SNN is not an isolated one. The High Free Cash Flow Stocks screen also flags the company, noting that SNN generates strong free cash flow relative to its market price. That fits with the article’s valuation work, where price/free cash flow stood out as one of the stock’s strongest inputs, and adds an independent layer of support: the cheap earnings multiple is backed by real cash generation.
Finding more Decent Value candidates
For investors who prefer a more systematic approach, the same screen can be run across the broader market. The methodology used to identify SNN is not a one-off guess; it is a repeatable set of filters that combines valuation with quality thresholds. The Decent Value screen currently lists other stocks that pass these tests and may be worth further analysis. With the S&P 500's long-term and short-term trends both positive, such screens can help investors find names that have lagged the wider market while still maintaining solid fundamentals.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Smith & Nephew (NYSE:SNN) Looks Undervalued on Decent Value Screen
The Decent Value screen applies a value investing discipline that goes beyond simply buying the lowest price-to-earnings ratio. The methodology starts with valuation but then requires that a company also demonstrates acceptable profitability, financial health, and growth. In other words, it is designed to find stocks that look cheap for a good reason rather than because the business is deteriorating. One name that currently stands out is SMITH & NEPHEW PLC -SPON ADR (NYSE:SNN), a medical device company active in orthopaedics, sports medicine, ENT, and advanced wound management.
What the Decent Value screen looks for
The screen begins with a valuation filter, looking for companies that score well on metrics such as price/earnings, forward earnings, EV/EBITDA, and price/free cash flow. But it then adds quality checks: the company must still show decent profitability, a reasonably healthy balance sheet, and at least moderate growth.
That combination matters because a low valuation is only meaningful if the underlying business can maintain its earnings power. Without those checks, value investors risk falling into a value trap, where a cheap stock stays cheap because fundamentals deteriorate.
Valuation: a cheap entry point relative to quality
SNN receives a valuation score of 7/10. On a trailing price/earnings basis, the stock trades at 19.29, below the industry average and well below the S&P 500's 26.27. The forward P/E is more striking at 10.85, which is cheaper than 94.12% of industry peers and far below the S&P 500 forward multiple of 21.76.
The valuation picture is also supported by other multiples:
The PEG ratio is flagged as less attractive, which is a reminder that the stock is not necessarily inexpensive on a growth-adjusted basis. Still, the company's strong profitability rating may justify a higher multiple than the market currently assigns.
Investors who want to dig deeper into these valuation inputs and the full peer comparison can review the fundamental analysis report.
Profitability and health: quality behind the price
SNN's profitability score is 8/10, its strongest fundamental area. The company has been profitable in each of the past five years and has generated positive operating cash flow over the same period. Return on assets is 5.77%, return on equity is 12.26%, and return on invested capital is 9.44%, each among the better results in its industry. An operating margin of 17.41% is particularly strong, outperforming more than 90% of industry peers.
Health is more mixed. SNN scores 6/10. An Altman-Z score of 3.06 suggests no immediate bankruptcy risk, and a current ratio of 2.14 points to adequate short-term liquidity. However, the quick ratio of 1.11 and a debt/equity ratio of 0.72 are less impressive relative to peers, while a debt/free cash flow ratio of 4.43 means it would take more than four years of free cash flow to repay current debt. These are not red flags, but they explain why the health rating is not higher.
For a value-oriented strategy, this trade-off is acceptable. A healthy balance sheet supports the idea that the company can keep funding its operations and dividend while the market eventually recognizes the underlying earnings power.
Growth: moderate but supportive
The growth score is 5/10, reflecting moderate but positive expansion. Last year, earnings per share grew 31.68%, while historical EPS growth comes in at 6.98% per year. Revenue grew 5.99% last year and 6.21% on average over prior years.
Looking forward, the report expects EPS growth of 8.89% per year and revenue growth of 5.98% per year. That implies a slight acceleration in earnings, which is relevant because it helps support the forward P/E of 10.85. Growth matters for the Decent Value methodology because it can close the gap between market value and intrinsic value over time, without relying on multiple expansion alone.
Key fundamental highlights
The report's overall fundamental rating for SNN is 7/10. The main data points supporting that score include:
Risks and limitations
Value investors should not ignore the less favorable parts of the report. The PEG ratio is elevated, which means the cheap trailing multiple may look less compelling once growth is factored in. Dividend sustainability is acceptable, but the payout ratio of 52.44% leaves limited room for aggressive increases.
In addition, some health metrics are not at the top of the industry, and the company remains exposed to competitive and regulatory pressures in medical devices. As with any value screen, the goal is to reduce risk, not eliminate it. Position sizing and a margin of safety remain important tools for investors who decide to act on this type of setup.
Other screens that reinforce the SNN value case
The Decent Value signal on SNN is not an isolated one. The High Free Cash Flow Stocks screen also flags the company, noting that SNN generates strong free cash flow relative to its market price. That fits with the article’s valuation work, where price/free cash flow stood out as one of the stock’s strongest inputs, and adds an independent layer of support: the cheap earnings multiple is backed by real cash generation.
Finding more Decent Value candidates
For investors who prefer a more systematic approach, the same screen can be run across the broader market. The methodology used to identify SNN is not a one-off guess; it is a repeatable set of filters that combines valuation with quality thresholds. The Decent Value screen currently lists other stocks that pass these tests and may be worth further analysis. With the S&P 500's long-term and short-term trends both positive, such screens can help investors find names that have lagged the wider market while still maintaining solid fundamentals.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »